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Transcriptional silencing of long noncoding RNA
GNG12-AS1 uncouples its transcriptional and
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Long noncoding RNAs (lncRNAs) regulate gene expression via their RNA product or through
transcriptional interference, yet a strategy to differentiate these two processes is lacking.
To address this, we used multiple small interfering RNAs (siRNAs) to silence GNG12-AS1, a
nuclear lncRNA transcribed in an antisense orientation to the tumour-suppressor DIRAS3.
Here we show that while most siRNAs silence GNG12-AS1 post-transcriptionally, siRNA
complementary to exon 1 of GNG12-AS1 suppresses its transcription by recruiting Argonaute
2 and inhibiting RNA polymerase II binding. Transcriptional, but not post-transcriptional,
silencing of GNG12-AS1 causes concomitant upregulation of DIRAS3, indicating a function in
transcriptional interference. This change in DIRAS3 expression is sufﬁcient to impair cell cycle
progression. In addition, the reduction in GNG12-AS1 transcripts alters MET signalling and cell
migration, but these are independent of DIRAS3. Thus, differential siRNA targeting of a
lncRNA allows dissection of the functions related to the process and products of its
transcription.
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T
he mammalian genome encodes many long noncoding
RNAs (lncRNAs) that play pivotal roles in gene regulation
during development and disease pathogenesis1–3.
LncRNAs can regulate gene expression through transcriptional
interference (TI)4,5 or through the RNA product itself1,2. TI
occurs when the act of transcribing a gene directly interferes with
the transcription of an adjacent gene in cis, either at its initiation
site or at an essential cis-regulatory element6,7. Transcription of
lncRNA has been shown to interfere with the transcription of
adjacent genes by altering the binding of transcription factors8–10
and/or RNA polymerase II (Pol II)11, nucleosome remodelling12
or inducing changes in histone modiﬁcations13,14.
So far, the strategies for demonstrating TI in mammalian cells
have relied upon genetic engineering methodologies that remove
the promoter region or insert premature transcriptional termina-
tion sites within the transcriptional unit4. An alternative
approach would be to leave the DNA template intact and
directly target the lncRNA with small interfering RNAs (siRNAs).
It is widely perceived that RNA interference (RNAi) is a
cytoplasmic pathway for post-transcriptional gene silencing15.
However, RNAi-based technology has been used to post-
transcriptionally deplete a lncRNA Kcnq1ot1 in the nucleus and
demonstrate that this lncRNA product is not required to
maintain imprinting of adjacent genes16. RNAi has also been
shown to induce transcriptional gene silencing (TGS)17–19.
siRNA-directed TGS can lead to epigenetic changes such as
DNA methylation and histone methylation at the target
promoters17,20–22. In addition, promoter-targeting siRNAs can
induce TGS by blocking the recruitment and the activity of Pol II
(refs 23–25). In all these cases, Argonaute proteins (AGO1 and
AGO2) were shown to be key players of TGS21,24,26–29. Finally, it
has been shown that siRNAs can be used to knockdown
small-nuclear ncRNA 7SK30. These observations prompted us
to investigate whether siRNAs can be used to inhibit lncRNA
transcription and to explore the functional consequences of this
process. In particular, we postulated that by targeting different
regions of the lncRNA, we could uncouple the act of transcription
from the function of the transcript. This would enable us to
investigate how lncRNAs regulate adjacent genes in cis through
TI. As a model, we used the imprinted tumour-suppressor
DIRAS3 locus, where we have recently characterized a novel
lncRNA known as GNG12-AS1 (ref. 31). GNG12-AS1 is
transcribed in an antisense orientation to DIRAS3 and its
neighbouring non-imprinted genes GNG12 and WLS (Fig. 1a).
We have shown that this lncRNA is allele speciﬁcally silenced in
cancer cell lines depending on the imprinted state of DIRAS3
(ref. 31). DIRAS3 (also known as ARHI and NOEY2) is a
Ras-related imprinted tumour suppressor involved in the
inhibition of growth, motility and invasion via several signalling
pathways including RAS/MAPK, STAT3 and PI3K32. DIRAS3 is
downregulated in 70% of breast and ovarian cancer33–35, and its
loss of expression correlates with cancer progression and
metastasis34,35. The mechanism responsible for DIRAS3
downregulation to date involves different epigenetic
mechanisms and loss of heterozygosity32. We hypothesized that
TI by GNG12-AS1 could represent an additional layer of
regulating DIRAS3 dosage.
Here, we demonstrate that GNG12-AS1 can be transcription-
ally silenced with siRNAs complementary to a region proximal
to its transcriptional start site (TSS). The transcriptional
silencing of GNG12-AS1, which is mediated by AGO2, leads
to upregulation of DIRAS3 transcription in cis, indicating a
function in TI. In contrast, targeting GNG12-AS1 at the 30 end
did not affect its nascent transcription, but reduced the lncRNA
through post-transcriptional gene silencing and, importantly,
did not affect DIRAS3 transcription. We further show different
phenotypic effects in cell cycle and migration depending on
whether we target the 50 or 30 end of GNG12-AS1. Altogether,
our results demonstrate that strategic targeting of siRNA to
different regions of an lncRNA can enable the discrimination
between functions related to its active transcription and that of
the RNA product.
Results
GNG12-AS1 is a stable lncRNA localized in the nucleus. In this
study, we used three non-cancer cell lines (HB2, HS27, MCF10A),
which we have previously shown to have normal imprinted
DIRAS3 expression, and breast cancer cell lines (SUM159,
MCF7), where loss of DIRAS3 imprinting leads to biallelic
expression (SUM159) or biallelic silencing of DIRAS3 (MCF7).
The non-cancer cell lines expressed GNG12-AS1 from both
alleles, whereas the cancer cell lines expressed GNG12-AS1 from
one allele31. We conﬁrmed the relative expression of DIRAS3,
GNG12, GNG12-AS1 and WLS in these cell lines (Supplementary
Fig. 1a). Actinomycin D chase experiments indicate that
GNG12-AS1 is a stable lncRNA with a half-life between 20 and
25 h (Supplementary Fig. 1b). DIRAS3 expression remained
unchanged in HB2 and increased in HS27 when cells were treated
with Actinomycin D, suggesting an inverse relationship
between DIRAS3 and GNG12-AS1 transcription. Despite being
a stable lncRNA, GNG12-AS1 has a low transcript volume
(20–80 molecules per 100 cells; Supplementary Fig. 1c).
Expression analysis following cell fractionation indicated that
GNG12-AS1 is localized within the chromatin (Fig. 1b), similar to
MALAT1, a lncRNA known to be associated with chromatin36.
Using single-molecule RNA ﬂuorescence in situ hybridization
(RNA FISH; as described in ref. 37), we conﬁrmed that GNG12-
AS1 is nuclear in HB2 and SUM159 cells. Exonic probes
complementary to all exons showed that GNG12-AS1
transcripts accumulate in the nucleus in discrete foci in 19% of
SUM159 and 25% of HB2 cells (Supplementary Fig. 1d).
Intronic RNA FISH probes complementary to the ﬁrst intron
of GNG12-AS1 were found to co-localize with the exonic signals
in about two-thirds of cases where both probes were present in
the same cell (6.8% in HB2 cells; 2.8% in SUM159 cells; Fig. 1c).
As intronic probes are usually indicative of nascent transcription
and exonic probes can detect both primary and mature
transcripts, their co-localization may indicate that the processed
transcript remains at its site of transcription, which would ﬁt with
GNG12-AS1 being co-transcriptionally spliced, as previously
reported31. However, as we also see separate signals for exonic
and intronic probes, it is likely that some GNG12-AS1 also
accumulate at other sites in the nucleus away from its site of
transcription (3.3% in HB2 cells; 1.7% in SUM159 cells; Fig. 1d).
A caveat to the interpretation of FISH data is that intronic and
exonic RNA FISH probes might not hybridize to nascent and
mature lncRNA transcripts in a mutually exclusive way. Nascent
RNA contains exons and the mature lncRNAs may be present as
unspliced isoforms.
In SUM159 cells, the intronic probe mostly produced a single
FISH signal (13% of cells being monoallelic, Supplementary
Fig. 1e), which ﬁts with previous pyrosequencing data reporting
allele-speciﬁc GNG12-AS1 expression in cancer cells31. By
contrast, in HB2 cells, even though pyrosequencing showed an
allelic ratio of 50% (ref. 31), we observed cells with both single
and double intronic signals (8 and 6% of cells, respectively;
Supplementary Fig. 1e), suggesting that GNG12-AS1 is
heterogeneously biallelic and randomly monoallelic at the
cellular level in HB2 cells. Together, these data conﬁrm that
GNG12-AS1 is a stable lncRNA that is present in the nucleus at
distinct foci.
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TI between GNG12-AS1 and DIRAS3. To investigate the
role of GNG12-AS1, we depleted GNG12-AS1 using
siRNAs (Fig. 2a). GNG12-AS1 has multiple isoforms31, thus we
designed siRNAs against several different exons and found that
siRNA targeted to exons 1, 5 and 7 reduced GNG12-AS1 by
50–70% in HB2 and SUM159 cells (Supplementary Fig. 2a–c).
These exons are common to all of the known splice forms
of GNG12-AS1. Using several primer sets to capture the
various GNG12-AS1 isoforms, we conﬁrmed that siRNAs
against exons 1 and 7 efﬁciently knockdown GNG12-AS1
(Supplementary Fig. 2d). We further conﬁrmed that the knock-
down occurred in all cellular compartments (Supplementary
Fig. 2e). Thus, we are able to deplete GNG12-AS1 in the nucleus
with siRNA.
RNA FISH analysis in SUM159 cells showed that although
siRNAs to either exon 1 or exon 7 effectively ablated GNG12-AS1
detectable with exonic probes, siRNA targeting exon 1 reduced
GNG12-AS1 detectable with intronic probes (nascent transcripts)
more efﬁciently than siRNA to exon 7 (Fig. 2b). These results
indicate that although both siRNAs can efﬁciently reduce
GNG12-AS1 levels in different cellular compartments, siRNA
complementary to the 50 end of GNG12-AS1 may preferentially
inhibit its nascent transcription.
We next asked whether depletion of GNG12-AS1 affects the
transcription of its neighbouring genes. We analysed the
expression of GNG12, DIRAS3 and WLS after depleting
GNG12-AS1 with siRNAs against exon 1 and exon 7. DIRAS3,
but not GNG12 orWLS, was upregulated after targeting exon 1 of
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Figure 1 | GNG12-AS1 is a stable lncRNA in the nucleus. (a) Schematic representation of the GNG12-AS1 genomic locus (chr1: 68297971–68668670,
hg19) relative to GNG12, DIRAS3 and WLS. The arrows show the direction of transcription. GNG12-AS1 exons are in green and are numbered as previously
reported31. Probes used for FISH are marked. Intronic, labelled in red identify the site of transcription. Exonic, labelled in green, mark mature transcripts. (b)
RNA distribution from the cytoplasm, nucleoplasm and chromatin in SUM159 cells as quantiﬁed by qRT–PCR. RPS18 and MALAT1 are positive controls for
the cytoplasmic and chromatin fraction, respectively. Note enrichment of GNG12-AS1 in the chromatin fraction. Relative RNA levels are standardized to the
geometric mean of GAPDH and b-actin. Error bars represent the s.e.m. values of three independent experiments. (c,d) Co-localization of exonic (green) and
intronic (red) GNG12-AS1 probes in HB2 and SUM19 cells by single-molecule RNA FISH. GNG12-AS1 associates with its site of transcription (2.8% in
SUM159, 6.8% in HB2; cis, c) but is also present at the other sites in the nucleus (1.7% in SUM159, 3.3% in HB2, trans, d). The numbers represent the
percentage of cells positive for exonic and intronic FISH signal (n¼ 132 for HB2; n¼ 176 for SUM159). The nucleus was stained with 4,6-diamidino-2-
phenylindole (DAPI). Scale bar, 7 mm.
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GNG12-AS1 in four cell lines (Fig. 2c,d and Supplementary
Fig. 3a–f). DIRAS3 upregulation was consistent in different cell
lines when GAPDH (Fig. 2c,d and Supplementary Fig. 3a,b) or the
geometric mean of GAPDH and RPS18 were used
(Supplementary Fig. 3c–f). Thus, for further quantitative real-
time PCR (qRT–PCR) experiments, we used GAPDH as the
reference gene. In a ﬁfth cell line MCF7, despite a 60% reduction
in GNG12-AS1, expression of DIRAS3 could not be reactivated
(Supplementary Fig. 4a). In MCF7 cells, DIRAS3 is more
hypermethylated at its promoter compared with SUM159 cells31.
Off-target effects were excluded by the use of additional siRNAs
against exon 1 and exon 7 of GNG12-AS1 (Supplementary
Fig. 4b). Furthermore, we used the randomized nucleotide
sequence (scrambled siRNAs) of exon 1 and exon 7 siRNAs
(Supplementary Fig. 4c,d), as well as C911 mismatch siRNA
controls38, all of which failed to affect GNG12-AS1 and DIRAS3
levels (Supplementary Fig. 4e).
To exclude the possibility of GNG12-AS1 regulating DIRAS3
expression in trans, we ectopically introduced GNG12-AS1 in
SUM159 and HB2 cells. Overexpression of the most common
splice variants of GNG12-AS1 had no effect on expression of
DIRAS3 or the surrounding genes (Supplementary Fig. 5a,b). As
DIRAS3 is an imprinted gene, we examined whether allele-
speciﬁc expression changed after GNG12-AS1 depletion. DIRAS3
imprinting and its methylation status were unaltered
(Supplementary Fig. 5c–e). Taken together, these results suggest
that GNG12-AS1 modulates the expression of the already active
DIRAS3 allele in cis and that siRNA to exon 1 of GNG12-AS1
disrupts this function without affecting expression of neighbour-
ing genes.
siRNA against 50 end of GNG12-AS1 blocks RNA Pol II. Next,
we examined whether inhibition of DIRAS3 in cis can be achieved
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Figure 2 | Transcriptional interference by GNG12-AS1 regulates DIRAS3. (a) The GNG12-AS1 locus where X indicates the exons targeted by siRNA. (b)
Changes in single-molecule RNA FISH signals after treating SUM159 cells with siRNA directed to exon 1 or exon 7 of GNG12-AS1. Changes in nascent
transcription after exon 1, but not exon 7 siRNA, of GNG12-AS1 were found using intronic probes (left panel). Both siRNAs decreased the number of exonic
FISH signal (right panel). Cells positive for intronic probes include cells with both mono and biallelic signal, and cells positive for exonic probes include cells
having one or more dots. The number of cells positive for RNA FISH signal is presented relative to control siRNA (control siRNA¼454 cells; exon 1
siRNA¼429 cells; exon 7 siRNA¼ 257 cells). (c,d) siRNA-mediated knockdown of exon 1 (50 targeting) and exon 7 of GNG12-AS1 (30 targeting) in HB2
(mammary epithelial cell line, c) and SUM159 (breast cancer cell line, d). Similar results were obtained in two additional cell lines (Supplementary
Fig. 3a,b). DIRAS3 is upregulated only when the 5’ end of GNG12-AS1 is targeted by siRNA directed to exon 1. For all the graphs, expression levels of DIRAS3,
GNG12, WLS, GNG12-AS1 were measured by qRT–PCR, normalized to GAPDH or to geometric mean of GAPDH and RPS18 (see also Supplementary Fig. 3c–f),
and are presented relative to control siRNA. Primers spanning exons 7–8 were used for GNG12-AS1 expression. RPS18 was used as a negative control gene
whose expression does not change upon siRNA treatment. Error bars, s.e.m. (n¼ 3 biological replicates). *Po0.05, **Po0.01, ***Po0.001 and
****Po0.0001 by two-tailed Student’s t-test.
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by targeting GNG12-AS1 exons closer to the DIRAS3 gene.
Similar to when we targeted exon 7, siRNA to exon 5 efﬁciently
reduced GNG12-AS1 (Supplementary Fig. 2b,c), but did not
upregulate DIRAS3 (Supplementary Fig. 6a,b). In one of the cell
lines, siRNA to exon 5 led to WLS downregulation. siRNAs to
exons 2 and 3, which ﬂank DIRAS3 on either side, reduced
GNG12-AS1 isoform speciﬁcally (Supplementary Fig. 2f,g),
suggesting that these siRNAs function post-transcriptionally. These
siRNAs had no effect on DIRAS3 expression further supporting
modulation via the act of transcription rather than through a
speciﬁc GNG12-AS1 isoform (Supplementary Fig. 6c,d).
To prove that the cis function of GNG12-AS1 is modulated
by siRNA targeting exon 1, which leads to the inhibition
of TI between GNG12-AS1 and DIRAS3, we proﬁled Pol II
and histone modiﬁcations. As shown in Fig. 3a,b, a signiﬁcant
reduction in Pol II binding was observed at the TSS of
GNG12-AS1 when exon 1, but not exon 7, was targeted by
siRNA. Concomitantly, an increase in Pol II binding was
observed at the DIRAS3 TSS. Nuclear run-on assays showed that
the reduction in Pol II binding was associated with reduced
nascent GNG12-AS1 transcription. Thus, a reduction of
GNG12-AS1 and increased DIRAS3 run-on transcripts
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as the percentage of protein bound, normalized to input. Neg ctrl¼ negative control region. Error bars, s.e.m. (n¼ 3 biological replicates). *Po0.05,
**Po0.01 and ****Po0.0001 by two-tailed Student’s t-test.
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were observed with siRNA targeting exon 1, but not exon 7
(Fig. 3c).
To determine whether we could ablate unspliced transcripts
and if so, whether this could affect DIRAS3 expression, we
designed siRNAs to the ﬁrst intron at 195 and 2,933 bp
downstream of the GNG12-AS1 TSS. In both HB2 and HS27
cell lines, these siRNAs resulted in a reduction of GNG12-AS1,
indicating that the unspliced GNG12-AS1 transcript can be
targeted by siRNA. However, increased DIRAS3 expression
occurred only in HS27 cells (Supplementary Fig. 7a,d), indicating
that siRNA speciﬁcally targeting exon 1 is more efﬁcient at
disrupting the regulatory relationship between GNG12-AS1 and
DIRAS3 transcription.
Consistent with the changes in Pol II binding, we observed
changes in active histone modiﬁcations when GNG12-AS1 was
depleted using siRNA against exon 1, but not with exon 7
(Fig. 3d,e). Histone H3 lysine 4 trimethylation (H3K4me3) was
reduced at the GNG12-AS1 TSS and increased at the DIRAS3 TSS.
Furthermore, histone H3 lysine 36 trimethylation (H3K36me3), a
marker for Pol II elongation39, was decreased in the body of
GNG12-AS1 and increased within DIRAS3. As GNG12-AS1
depletion with exon 1 siRNA did not affect WLS expression, a
reduction in H3K36me3 at 30 end of GNG12-AS1 correlates with
reduction in its transcriptional activity. The reduction of active
histone modiﬁcations at the GNG12-AS1 TSS was not
accompanied by a reciprocal increase of silencing modiﬁcations
previously reported to be involved in TGS20,21,29, such as histone
H3 lysine 9 trimethylation (H3K9me3) and histone H3 lysine 27
trimethylation (H3K27me3; Supplementary Fig. 8a,b). In
addition, DNA methylation was unchanged at the GNG12-AS1
TSS (Supplementary Fig. 8c).
The changes in Pol II binding at the TSS of GNG12-AS1,
together with the changes in active histone modiﬁcations
associated with transcriptional activity after siRNA to exon 1,
suggest that targeting the 50 end of this lncRNA results in
transcriptional silencing. However, to date, in all instances of TGS
with exogenous siRNAs in human cells, the siRNAs were directed
to the gene promoters. We therefore designed two siRNAs
targeting GNG12-AS1 upstream of the TSS (33 and 129 bp
upstream of TSS). These siRNAs had no effect on GNG12-AS1
expression (Supplementary Fig. 7c,d), suggesting that transcrip-
tion needs to be initiated for effective knockdown of the lncRNA.
In summary, siRNA targeting speciﬁcally exon 1 of GNG12-AS1
reduced its nascent transcription, without inducing changes
in silent chromatin marks. Nevertheless, reduced transcription
was associated with diminished Pol II activity and the
redistribution of active histone marks, which led to increased
DIRAS3 expression.
AGO2 mediates transcriptional inhibition of GNG12-AS1. As
TGS is achieved through the RNAi machinery24,25,27,28, we
investigated whether siRNA-mediated silencing of GNG12-AS1
involves Argonaute proteins. First, we examined whether the
reduction in GNG12-AS1 transcript by siRNA targeted to exon 1
could be rescued by depletion of AGO1/2 proteins. We found that
depletion of AGO2 rescued GNG12-AS1 expression in cells
exposed to siRNAs against exon 1 and exon 7 and abolished
DIRAS3 upregulation in cells treated with siRNA against exon 1
(Fig. 4a). This effect was speciﬁc to AGO2, as AGO1 depletion
did not rescue GNG12-AS1 depletion or DIRAS3 levels
(Supplementary Fig. 9a). Similar results were obtained in the
HS27 cell line (Supplementary Fig. 9b,c), conﬁrming that AGO2
is involved in both the transcription- and post-transcription-
mediated mechanism of siRNA-directed downregulation of
GNG12-AS1.
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We veriﬁed that AGO2 is present in the nucleus and cytoplasm
(Supplementary Fig. 9d), as previously reported18. Next, we used
chromatin immunoprecipitation (ChIP) analysis to see whether
AGO2 associates with the GNG12-AS1 locus. We found that
AGO2 was recruited to the GNG12-AS1 TSS only after treatment
with siRNA directed to exon 1, but not exon 7 (Fig. 4b). This
result suggests that AGO2 facilitates the physical interaction
between exogenous siRNA to exon 1 and the chromatin to
potentially mediate TGS of GNG12-AS1. Finally, we tested
whether GNG12-AS1 associates with AGO2 in the nucleus.
RNA immunoprecipitation (RIP) for AGO2 in nuclear extracts
transfected with siRNAs showed an interaction between
GNG12-AS1 and AGO2 only when siRNA targeted exon 1, and
not exon 7 (Fig. 4c). Taken together, these results demonstrate
that AGO2 mediates transcriptional silencing of GNG12-AS1 by
siRNA complementary to exon 1.
Cell cycle regulation by GNG12-AS1. DIRAS3 has been
implicated in cell cycle regulation40, so we next asked if
expression levels of DIRAS3 and GNG12-AS1 might correlate
at different stages of the cell cycle. We synchronized cells
with a double thymidine block (Fig. 5a), which arrest cells in
S-phase and used cyclin E1 (G1/S transition marker) to monitor
cell cycle progression (Fig. 5c). An increase in GNG12-AS1
transcription was observed after the release from double
thymidine block, which coincided with the downregulation of
DIRAS3. Cell cycle synchronization using serum starvation,
followed by release with serum-containing media, showed
similar results (Fig. 5b,d). The inverse relationship between
expression levels of GNG12-AS1 and DIRAS3, which was tightly
maintained throughout the cell cycle, further supports the
evidence that GNG12-AS1 transcription modulates DIRAS3
expression in cis through TI.
We next examined the consequence of upregulating DIRAS3
after inhibiting GNG12-AS1. When GNG12-AS1 was depleted
with exon 1 siRNA, we observed a small decrease in G1 cell
number (control siRNA: 34% versus exon 1 siRNA: 29%;
P¼ 0.0575; Fig. 5e,f). This result was conﬁrmed by qRT–PCR
and immunoblot analysis, which showed decreased cyclin E1
levels (Fig. 5g–i). As expected, by combining siRNAs to DIRAS3
and exon 1 siRNA, we were able to neutralize the increase in
DIRAS3 expression (Fig. 5g–i), which led to a modest but
signiﬁcant restoration of the G1 population (exon 1 siRNA: 29%
versus exon 1/DIRAS3 siRNA: 36%, P¼ 0.0105; Fig. 5f). Analysis
of cyclin E1 levels showed that the reduction in G1 cell numbers
could be partially rescued with the simultaneous depletion of
GNG12-AS1 and DIRAS3 (Fig. 5g–i). By contrast, cyclin B1 levels
did not differ among GNG12-AS1- and DIRAS3 siRNA-treated
cells. Both RNA and protein levels of the cell cycle inhibitor p21
increased when the cells were treated with siRNA to exon 1 in a
DIRAS3- independent manner. S-phase distribution was
unchanged after reducing GNG12-AS1. However, both exon 1
and exon 7 siRNAs increased the G2/M population (control
siRNA: 23% versus exon 1 siRNA: 35%, P¼ 0.0009; or versus
exon 7 siRNA: 30%, P¼ 0.0126). As the increase in G2/M
population occurred upon simultaneous depletion of GNG12-AS1
and DIRAS3 (control siRNA: 23% versus exon 1/DIRAS3 siRNA:
29%, P¼ 0.0169; or versus exon 7/DIRAS3 siRNA: 30%,
P¼ 0.0084), we concluded that this G2/M delay is a
DIRAS3-independent event.
Taken together, these data indicate that GNG12-AS1 has a dual
function in controlling cell cycle progression. Transcription of
GNG12-AS1 inﬂuences the G1 phase of the cell cycle by
modulating DIRAS3 expression, whereas the effect on G2/M
phase of the cell cycle by GNG12-AS1 is a DIRAS3-independent
event, and most likely represents the function of the RNA
product.
GNG12-AS1 has a trans function regulating cell migration.
DIRAS3 overexpression has been linked to cell migration and cell
proliferation32, so we assayed these cellular phenotypes after
GNG12-AS1 knockdown. We found that reducing GNG12-AS1
with either of the siRNAs increased cell migration (Fig. 6a). As no
difference was seen between the two siRNAs, we conclude that
these phenotypic effects are due to the reduction of GNG12-AS1
transcripts and independent of DIRAS3. Indeed, a change in the
migration phenotype was also observed in MCF7 cells, where
DIRAS3 silencing cannot be reversed by GNG12-AS1 depletion
(Fig. 6a). We next proﬁled global transcription changes after
knockdown of GNG12-AS1 and found that both siRNAs against
this lncRNA induced signiﬁcant changes in cell adhesion and
actin cytoskeleton pathways (Supplementary Fig. 10a,b). We
focused on mesenchymal epithelial transition factor (MET), a
tyrosine kinase receptor for the hepatocyte growth factor, known
to regulate cell migration and invasion41,42 and found increased
levels of MET (Fig. 6b,c and Supplementary Fig. 10c). In line with
MET activation, we found elevated levels of theMET downstream
target MAP2K4 (mitogen-activated protein kinase kinase 4)42.
This suggests that activation of MET signalling and its
downstream targets could be responsible for the observed
changes in cell migration. Interestingly, reducing speciﬁc minor
isoforms of GNG12-AS1 containing exons 2 and 3 was sufﬁcient
to trigger activation of this signalling pathway. Future research
into the secondary structure of the GNG12-AS1 will determine if
this function is isoform speciﬁc. Finally, we examined whether
simultaneously depleting GNG12-AS1 and DIRAS3 would prevent
MET activation. Increased MET protein levels were maintained,
conﬁrming that GNG12-AS1 regulates MET signalling
independently of DIRAS3 (Supplementary Fig. 10d). Altogether,
these data indicate that the GNG12-AS1 transcript inhibits cell
migration. In this context, GNG12-AS1 may have a tumour-
suppressor function in addition to a role in modulating the
expression levels of DIRAS3.
Discussion
LncRNAs can function via their RNA product and through the
act of their transcription. So far it has been challenging to tease
apart these two processes. Here we employed an siRNA-based
strategy targeting different regions of GNG12-AS1 and found that
siRNA selectively targeting the ﬁrst exon of GNG12-AS1 resulted
in increased expression of DIRAS3 in cis. These ﬁndings, together
with inverse relationship between GNG12-AS1 and DIRAS3
during the cell cycle and Actinomycin D treatment, indicate that
the act of transcribing GNG12-AS1 regulates expression of the
active DIRAS3 allele by TI. We subsequently showed that this
transcriptional targeting by siRNA to the 50 end of GNG12-AS1 is
mediated by AGO2, which binds to the GNG12-AS1 TSS as well
as to its transcript. Finally, distinct functional consequences were
uncovered, depending on whether GNG12-AS1 transcription was
disrupted or whether its product was depleted.
The ﬁrst suggestion that siRNA targeting exon 1 of
GNG12-AS1 reduced its nascent transcription was with
RNA-FISH, where we observed reduced hybridization with
intronic probes after treating cells with this siRNA. More
concrete biochemical evidence of transcriptional inhibition were
demonstrated by decreased Pol II binding at the GNG12-AS1 TSS
with ChIP and reduced nascent transcription with nuclear run-on
experiments. siRNA targeted to exon 7, while still reducing the
overall GNG12-AS1 product, does not upregulate DIRAS3 and
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does not change Pol II binding, making this siRNA an excellent
internal control for our experiments.
Consistent with the data on Pol II binding and nascent
transcription, we detected a reduction in the active histone
modiﬁcation, H3K4me3 at the GNG12-AS1 TSS when
GNG12-AS1 was depleted using siRNA against exon 1, but not
with exon 7. Similarly, the histone modiﬁcation mark H3K36me3,
which normally accumulates in gene body where it is associated
with transcriptional elongation39, was reduced at the 30 end of
GNG12-AS1. Thus, our ﬁndings suggest that siRNA targeting the
50 end of GNG12-AS1 led to inhibition of transcriptional
initiation and elongation of GNG12-AS1 by directly interfering
with Pol II dynamics without inducing changes in DNA
methylation and repressive histone marks.
To date, all reported cases of exogenous TGS in human cells
have used siRNAs against the gene promoter regions or the
TSS17,20,24,25,29. Our study is, therefore, the ﬁrst to show that
targeting the ﬁrst exon interferes with the transcription of a
lncRNA. Indeed, with GNG12-AS1, targeting regions upstream of
the TSS had no effect on its transcription, suggesting that
transcription needs to be initiated in order to be targeted by
siRNA. This may also explain why, although we found a
reduction in active histone modiﬁcations, we did not observe
an increase in repressive chromatin marks.
As TGS is achieved through the RNAi machinery24,25,27,28, we
investigated the engagement of AGO2 in the inhibition of
GNG12-AS1 transcription. siRNAs are known to form a complex
with AGO2 in the cytoplasm and then shufﬂe between the
cytoplasm and nucleus43. Small-RNA loading is a cytoplasmic
process necessary for the nuclear import of AGO2 (refs 18,43,44).
It has further been suggested that small RNAs can guide AGO2 to
the promoters of ncRNAs and affect their transcription45,46.
Based on these precedents, we would expect that all siRNAs in
our experiments would have a similar knockdown efﬁciency in
different cellular compartments, and once the AGO2–siRNA
complex was in the nucleus, the functional consequences of the
GNG12-AS1 depletion would depend on the region targeted. The
presence of AGO2–siRNA complexes in the nucleus and
cytoplasm would explain why we could rescue the GNG12-AS1
expression in double knockdown experiments between
GNG12-AS1 and AGO2. However, AGO2-siRNA-GNG12-AS1
complexes at the GNG12-AS1 TSS could only be detected in the
nucleus when the siRNA was directed to exon 1.
As described above, GNG12-AS1 could only be reduced when
sequences downstream of its TSS were targeted by siRNA. This
ﬁnding, together with the RIP results, showing that AGO2
associates with the GNG12-AS1 when cells are treated with siRNA
to exon 1, suggest that transcription needs to have been already
initiated for siRNA-mediated repression of transcription.
Although AGO2–siRNA interactions with chromatin and the
lncRNA could be demonstrated by ChIP and RIP, respectively, we
do not have direct evidence for siRNA–AGO2 attaching the
nascent lncRNA to the chromatin. We propose a model described
in Fig. 7, where exogenous siRNA complementary to the 50 end
(exon 1) of GNG12-AS1 recruits AGO2 to GNG12-AS1 and to the
chromatin at its TSS. This complex, containing the siRNA and
GNG12-AS1 and possibly other proteins, stalls transcription of
GNG12-AS1 by Pol II. DIRAS3 expression is enhanced as a
consequence of reduced GNG12-AS1 transcription.
There are two possible mechanisms whereby an exogenous
siRNA in a complex with AGO2 could lead to decreased
GNG12-AS1 transcription. AGO2 has slicer activity47 and this
could promote cleavage and degradation of the nascent
GNG12-AS1. Alternatively, the AGO2–siRNA complex could
present a physical block for Pol II initiation and elongation at the
GNG12-AS1 TSS. Indeed, AGO2 has been shown to guide small
RNAs to inhibit Pol II recruitment and elongation in human
cells24,48 independently of its slicer activity24,27,45,46. AGO2 has
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been reported to form a complex with different chromatin-
modifying proteins to mediate gene silencing49. It is therefore
possible that AGO2–siRNA–GNG12-AS1 complexes at the TSS
may include further proteins that inﬂuence Pol II kinetics. Our
model does not distinguish between these different but not
necessarily mutually exclusive mechanisms.
Silencing of imprinted genes is frequently achieved by TI of an
antisense lncRNA11,50. In these cases, the lncRNA is reciprocally
imprinted relative to its target gene and is expressed on the
opposite allele. Unlike, the other imprinted genes, we found that
it was the already actively expressing DIRAS3 allele being
upregulated after GNG12-AS1 knockdown, indicating that
GNG12-AS1 has a role in modulating DIRAS3 expression in cis,
rather than maintaining its imprinting. A reduction of Pol II and
H3K4me3 at the TSS of GNG12-AS1 was associated with a
concomitant increase at the DIRAS3 TSS. These shifts reﬂect the
change in dynamics between these two genes as transcription
inhibition by the GNG12-AS1 is eased and DIRAS3 transcription
is augmented. TI between GNG12-AS1 and DIRAS3 could only be
consistently inhibited when siRNAs were target within the ﬁrst
exon of GNG12-AS1. Targeting the adjacent intron did not
lead to DIRAS3 upregulation in both of the cell lines tested. As
GNG12-AS1 was efﬁciently reduced, we presume the nascent
transcript was targeted, but GNG12-AS1 may also be present as
mature unspliced transcripts that can be targeted post-
transcriptionally. There are several enhancer signature peaks
(histone H3 lysine 4 monomethylation (H3K4me1) and histone
H3 lysine 27 acetylation (H3K27ac)) within this intron as
annotated in the ENCODE database (Supplementary Fig. 11). It is
possible that although the nascent RNA can be inhibited by
siRNA targeted to this region, enough transcription has already
occurred through the region to prevent DIRAS3 upregulation. In
a region with multiple enhancers, some are likely to be tissue
speciﬁc, which could explain why DIRAS3 expression is
differentially upregulated in two different cell lines. The
presence of enhancer marks at this locus would ﬁt with
GNG12-AS1 being an enhancer-like, cis regulator of DIRAS3
transcription51. The location of these enhancers and their
potential speciﬁcity for DIRAS3 might explain why GNG12 is
not affected by GNG12-AS1 depletion. Another possibility is that
GNG12-AS1 expression is limited by GNG12 transcription and its
further reduction has no impact on GNG12 expression.
An alternative strategy to siRNA for analysing the cis functions
of GNG12-AS1 would have been to use CRISPRi, a new
technology involving small guide RNAs to recruit a catalytically
inactive Cas9 (dCas9) fused to the KRAB transcriptional
repressor domain to speciﬁc loci52. Similar to RNAi, CRISPRi
does not affect the underlying gene sequence and was shown to
induce transcriptional repression of lncRNAs52. However, KRAB-
mediated silencing can spread to adjacent genes53, which would
confound the detection of genes inﬂuenced by TI by a lncRNA.
Transcription of lncRNA provides an important mechanism
for ﬁne-tuning the expression of genes in cis54. There is evidence
for lncRNAs having a threshold-depended role in moderating
gene regulation rather than an activating or repressive role54. For
example, MALAT1, a lncRNA with several roles in gene
regulation, has subtle effects on the expression of its
neighbouring genes55. A ﬁne-tuning mechanism could explain
why small changes in gene expression observed after depletion of
some lncRNAs could be relevant upon speciﬁc stress or
environmental conditions. Imprinted genes are exquisitely
regulated for gene dosage. It is likely that in vivo, the cis
regulatory function of GNG12-AS1 in ﬁne-tuning DIRAS3
expression is limited to speciﬁc developmental stages or
environmental conditions as shown for HOTTIP lncRNA56,
which has similarly low abundance and expression levels.
GNG12-AS1 is not imprinted in non-cancer cell lines, as shown
previously by pyrosequencing SNP analysis31, but our RNA-FISH
results indicate that in a substantial proportion of HB2 cells it
may be randomly monoallelic. A growing number of autosomal
genes are being shown to be randomly monoallelic at single-cell
level57. If 50% of cells with GNG12-AS1 expression are expressing
transcripts from the paternal allele, these would be repressing
DIRAS3 in cis by TI, whereas on the other 50% of cells where
GNG12-AS1 expression is maternal, DIRAS3 would already be
silent on this allele. This would be consistent with the suggestion
that random monoallelic expression reﬁnes gene expression levels
in a population of cells58,59.
In addition to GNG12-AS1 having a cis function in moderating
DIRAS3 transcription, GNG12-AS1 also regulates cell cycle
progression. Transcriptional upregulation of DIRAS3 induced
by GNG12-AS1 depletion led to G1 delay associated with the
downregulation of cyclin E1. As the G1 delay and cyclin E1 levels
were rescued by simultaneous depletion of exon 1 siRNA of
GNG12-AS1 and DIRAS3, these data suggest that TI between
GNG12-AS1 and DIRAS3 contributes to the regulation of G1
phase of the cell cycle. DIRAS3 was shown to be involved in cell
cycle progression40,59. The upregulation of DIRAS3 by inhibiting
GNG12-AS1 transcription in our study does not have the same
effect on cyclin genes as previously reported, where DIRAS3 was
ectopically overexpressed40,59,60. These differences could be due
to the modest upregulation of DIRAS3 induced by transient
repression of GNG12-AS1 with siRNA, whereas the latter study
ectopically expressed DIRAS3. Nevertheless, our results are
consistent with a role for DIRAS3 in cell cycle progression
through G1 phase40,59. More importantly, these results indicate
that disruption of TI between GNG12-AS1 and DIRAS3 can have
effects on the cell cycle.
RNA-FISH analysis indicated that, in addition to co-localiza-
tion between intronic and exonic probes, we also found cells in
which the signals were separated, suggesting that there may be
additional functions for GNG12-AS1. Our cell cycle analysis
revealed that GNG12-AS1 depletion with siRNAs to 50 end and
30 end resulted in a G2/M delay. This effect is most likely due to a
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Pol II
PoI II
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Figure 7 | Inhibition of transcriptional interference with siRNA. The top
panel depicts how GNG12-AS1 modulates the expression of the active
DIRAS3 allele through transcriptional interference. GNG12-AS1 may act as a
rheostat for DIRAS3 transcription rate. The lower panel depicts how
exogenous siRNA molecules in a complex with AGO2 can bind to both the
TSS and GNG12-AS1 to inhibit Pol II, and block further transcription initiation
and elongation of GNG12-AS1. As a result of transcriptional silencing of
GNG12-AS1, transcriptional interference is reduced leading to increased
transcription of DIRAS3.
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DIRAS3-independent function of GNG12-AS1 RNA product. This
is further supported by our microarray experiments where both
siRNAs induced changes in genes involved in cell cycle
progression.
In addition, we found that reducing the levels of GNG12-AS1
transcripts whether by siRNAs directed to exon 1 or various other
exons of GNG12-AS1 resulted in increased cell migration. This
phenotype was observed upon GNG12-AS1 knockdown even in
cells where DIRAS3 expression was absent. Expression proﬁling
of GNG12-AS1-depleted cells showed an enrichment for genes
involved in cell adhesion, migration and actin cytoskeleton
pathways. We were able to validate the upregulation of MET
signalling pathway after siRNA-mediated reduction of GNG12-AS1.
MET controls many biological functions such as cell migration,
invasion and motility, and its aberrant activation can lead to
cancer41,42,61. We have previously shown that GNG12-AS1 is
downregulated in breast cancer tumours together with DIRAS3 (ref.
31). Thus, it is possible that GNG12-AS1 extends the tumour-
suppressor function of this locus by regulating oncogenes such as
MET. In keeping with this, MET was recently shown to be
regulated by MEG3 lncRNA in pancreatic tumours62. Thus, MET
could be a common target of lncRNAs involved in the regulation of
cellular processes important for tumour growth. Further
experiments are necessary to investigate whether the GNG12-AS1
transcript directly interacts with distant genes, and if so whether
this interaction is isoform speciﬁc.
In summary, GNG12-AS1 is similar to several other lncRNAs
that have both cis and trans functions63,64. Although the trans
function may be to regulate genes involved in cell cycle and cell
migration through direct interaction, the cis function has a role in
ﬁne-tuning regulation of DIRAS3 transcription. Altogether, our
results demonstrate that an siRNA-based strategy can be
employed to successfully separate functions that are due to
lncRNA transcription from those of the transcript.
Methods
Cell culture and treatments. HB2 (human mammary epithelial cell line) were
cultured in DMEM (GIBCO) supplemented with 10% fetal bovine serum (FBS),
10ml l 1 penicillin–streptomycin solution, 5mgml 1 insulin (Sigma) and
1mgml 1 hydrocortisone (Sigma). MCF10A (human breast epithelial cell line)
were cultured in MEGM SingleQuots (Lonza). SUM159 (breast cancer cell line)
were cultured in Ham’s F-12 medium (GIBCO) supplemented with 5% FBS,
5mgml 1 insulin and 1mgml 1 hydrocortisone; MCF7 (breast cancer cell line)
and HS27 (human foreskin ﬁbroblasts) were cultured in DMEM with 10% FBS and
10ml l 1 penicillin–streptomycin solution. 293FT cells were grown in DMEM
(high glucose 1 ; GIBCO, ref. 41965039) supplemented with 10% FBS, 0.1mM
MEM Non-Essential Amino Acids (GIBCO), 6mM L-glutamine (GIBCO), 1mM
MEM Sodium Pyruvate (GIBCO) and 500mgml 1 Geneticin (GIBCO). All the
cells were from American Type Culture Collection and were cultured at 37 C with
5% CO2. The cells were treated with Actinomycin-D (Sigma) at a ﬁnal con-
centration of 10mgml 1 for 0, 2, 6, 8 and 24 h.
Single-molecule RNA FISH. RNA FISH was performed as described37. Cells were
grown on 18mm round #1 cover glass, brieﬂy washed with PBS and ﬁxed with
PBS/3.7% formaldehyde at room temperature for 10min. Following ﬁxation, cells
were washed two times with PBS. The cells were then permeabilized in 70%
ethanol for at least 1 h at 4 C. Stored cells were brieﬂy rehydrated with Wash
Buffer (2 saline sodium citrate buffer (SSC), 10% formamide) before FISH. The
Stellaris FISH Probes (GNG12-AS1 intronic (Q670) and exonic probes (Q570),
sequences in Supplementary Table 1) were added to the hybridization buffer (2
SSC, 10% formamide, 10% dextran sulfate) at the same time to give a ﬁnal
concentration of 250 nM per probe set. Hybridization was carried out in a
humidiﬁed chamber at 37 C overnight. The following day, the cells were washed
twice with Wash Buffer at 37 C for 30min each. The second wash contained 4,6-
diamidino-2-phenylindole for nuclear staining (5 ngml 1). The cells were then
brieﬂy washed with 2 SSC and then mounted in Vectashield (Vector
Laboratories, H-1000). Images were captured using Nikon TE-2000 inverted
microscope with NIS-elements software using a Plan Apochromat  100 objective
and Andor Neo 5.5 sCMOS camera. We acquired 25 optical slices at 0.3 mm
intervals. Images were deconvolved with Huygens Professional and projected in
two dimensions using Volocity Image Software Analysis. Intronic signals
were scored to determine the percentage of cells with mono- or biallelic
expression. Exonic signals were then scored on the same cells. To score
whether intronic and exonic signals co-localize, we selected cells in which both
signals were present.
Quantitative real-time PCR. RNA (1mg) was extracted with the RNeasy Kit
(QIAGEN) and treated with DNase I (QIAGEN) following the manufacturer’s
instructions. QuantiTect Reverse Transcription Kit (QIAGEN) was used for cDNA
synthesis including an additional step to eliminate genomic DNA contamination.
Quantitative real-time PCR was performed on a 7900HT Fast Real-Time PCR
System (Applied Biosystems) with Fast SYBR Green Master Mix (Life Technolo-
gies). Thermocycling parameters: 95 C for 20 s followed by 40 cycles of 95 C for
1 s and 60 C for 20 s. Two reference genes (GAPDH and RPS18) were selected. Our
microarray data show no signiﬁcant variation in GAPDH and RPS18 expression in
our siRNA experiments in HB2, HS27 and SUM159 cells. Expression levels of
GNG12-AS1, DIRAS3, GNG12 and WLS in non-cancer and cancer cell lines are
normalized relative to the geometric mean of GAPDH and RPS18 (Supplementary
Fig. 1a). The expression levels using either GAPDH (Fig. 2c,d and Supplementary
Fig. 3a,b) or the average of GAPDH and RPS18 (Supplementary Fig. 3c–f) across
siRNA conditions were consistent and reproducible. Thus, we used only GAPDH
normalization for further experiments. Exon 7–8 of GNG12-AS1 was used to
quantify its expression, if not stated otherwise. To calculate the GNG12-AS1 copy
number, standard curve of Ct values was performed by qRT–PCR using dilution
series of known concentration of GNG12-AS1 DNA template (variant 1 that
contains exon 1, 2, 3, 4, 5, 6, 7, 8, 8b and 9). cDNA was made from RNA extracted
from known number of different cell lines. The Ct values were ﬁtted on the
standard curve and the number of GNG12-AS1 molecules per cell was calculated.
The ﬁnal value was multiplied by 2, to account for the fact that cDNA is single
stranded and DNA templates used to make standard curve is double stranded. The
sequences for expression primers are listed in Supplementary Table 2. The
ampliﬁcation efﬁciency of housekeeping genes was measured with serial dilution of
cDNA of each gene from ﬁve different cell lines. PCR efﬁciencies and correlation
coefﬁcients (R2) for each primer pair are shown in Supplementary Table 3.
RNA interference. The sequences of siRNAs are present in the Supplementary
Table 4. The cells were transfected with DharmaFECT 1 (SUM159, MCF7,
MCF10A), DharmaFECT 3 (HS27) or DharmaFECT 4 (HB2) (Thermo-Scientiﬁc)
following the manufacturer’s instructions. All experiments were done 48 h after
transfection and all the siRNAs were used at a ﬁnal concentration of 50 nM.
siRNA-mediated depletion of GNG12-AS1. RNA and proteins were fractionated
as described previously65. The cells were either untreated (for immunoblot
analysis) or transfected with control and GNG12-AS1 siRNAs (for RNA analysis).
RNA was isolated from cytoplasmic, nucleoplasmic and chromatin fractions by
TRIZOL extraction (Life Technologies) and used for qRT–PCR. Data were
normalized to the geometric mean of GAPDH and b-actin levels in each cellular
compartment as no normalization controls is equal in all three compartments
(for details see ref. 65). MALAT1 and RPS18 were used as positive controls for
chromatin and cytoplasmic fractions, respectively. Primers used for this assay are
listed in Supplementary Table 2.
Nuclear run-on assay. Nuclear run-on assay was performed as described
previously66. Cells were grown in 10 cm dishes, trypsinized and centrifuged, and
the pellets were washed with 1.5ml of NP-40 lysis buffer (10mM Tris-HCl, 10mM
NaCl, 3mM MgCl2, 0.5% NP-40), incubated on ice for 5min and centrifuged at
1,500g for 5min. Pellets were then washed again with 1.5ml NP-40 lysis buffer.
The nuclei pellets were resuspended in 70 ml glycerol storage buffer (50mM
Tris-HCl, pH 8, 0.1mM EDTA, 5mM MgCl2, 40% glycerol) and ﬂash frozen in
liquid nitrogen. 60 ml were transferred to fresh nuclease-free tubes and equal
amount of the 2 run-on transcription buffer (20mM Tris-HCl, pH8; 5mM
MgCl2, 300mM KCl, 4mM dithiothreitol) was added together with 2mM ATP,
CTP, GTP (GE Healthcare) and 1mM Biotin-16-UTP (Epicentre). The reaction
was incubated at 30 C for 45min. In vitro transcription was stopped by adding
TURBO DNase (Ambion) at 37 C for 30min. Then 100ml of nuclei lysis buffer
(50mM Tris-HCl, pH 7.5; 5% SDS, 0.125M EDTA) and Proteinase K (Ambion)
were added to the sample and incubated at 37 C for 30min. RNA extraction was
performed using phenol/chloroform/isoamyl alcohol: 25:24:1 (Invitrogen) and
chloroform/isoamyl alcohol: 24:1 (Sigma). To precipitate RNA, 3M sodium acetate
pH 5.5 (Life Technologies), GlycoBlue (Life Technologies) and ice-cold 100%
ethanol were added. The samples were incubated at  80 C for 30min and
centrifuged at 12,000g for 15min. Pellets were washed with ice-cold 70% ethanol
and centrifuged at 12,000g for 10min. The pellets were then resuspended in 30 ml
nuclease-free water. RNA samples were then puriﬁed on column using RNeasy kit
(Qiagen) to remove free Biotin-16-UTPs, according to the manufacturer’s
instructions. Puriﬁed RNA from column was eluted in 30 ml nuclease-free water.
Biotinylated RNA from samples was captured using Dynabeads MyOne C1
streptavidin beads (Invitrogen). C1 beads (40 ml per sample) were washed twice
with Solution A (100mM NaOH, 50mM NaCl) for 3min and once with Solution B
(100mM NaCl). The C1 beads were then preblocked with BSA (200 mgml 1) and
Yeast tRNA (200 mgml 1; Invitrogen) mix in Solution B. The beads were
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pre-blocked on a rotor at room temperature for 30min, collected on magnetic
stand and resuspended in Solution B. Beads were aliquoted into nuclease-free tubes
and equal amount (20 ml) of RNA was added. Biotinylated RNA was pulled down
for 2 h at room temperature. Then the beads were collected on magnetic stand,
washed three times with 1 Wash/Binding buffer (2 Wash/Binding buffer:
10mM Tris-HCl, pH 7.4; 1mM EDTA, 2M NaCl). After the ﬁnal wash, C1 beads
with bound RNA were eluted in 30 ml nuclease-free water and used directly for
reverse transcription to prepare cDNA. Relative transcription was calculated as:
2^  [MeanCt(gene)-MeanCt(b-actin )]. For GNG12-AS1 knockdown
experiments, control transcription was set to 1. b-Actin primer was used for
normalization (primers are listed in Supplementary Table 2).
Lentivirus overexpression of GNG12-AS1 in human cells. The different
GNG12-AS1 splice variants and negative control vector (scrambled sequence) were
ﬁrst cloned in pJET1.2 plasmid (Fermentas) and then into modiﬁed pLenti6.3/TO/
V5-DEST vector (kindly provided by John Rinn, Harvard University) using
Gateway cloning strategy. The sequences are listed in Supplementary Data 1. The
modiﬁed vector does not contain WPRE, the SV40 promoter and the blasticidin-
resistance gene that could interfere with lncRNA structure and function. Sanger
sequencing and restriction digestion using PvuI-HF and BsrGI enzymes conﬁrmed
the GNG12-AS1 inserts. Lentiviral transduction of GNG12-AS1 clones was done in
293FT cells using ViraPower (Invitrogen) including, negative and positive control
vector containing mCherry. The DNA-Lipofectamine2000 complexes were added
to 293FT cells and incubated overnight. Forty-eight and seventy-two hours post
transfection, the virus-containing supernatants were harvested, centrifuged at 700g
for 5min at 4 C and ﬁltered with 0.45 mm with additional 0.22 mm ﬁlter before
being stored at 4 C. To transduce SUM159 cells, 80,000 cells per 12-well plate were
seeded in triplicate and transduced with the lentiviruses at a multiplicity of
infection of 0.1 together with polybrene (5 mgml 1, Sigma). Transduction efﬁ-
ciency (480%) was veriﬁed using positive control vector containing mCherry and
measured by FACS Calibur Inﬂux (Beckton Dickinson) using BDFACS Software
1.0.0.650. The FACS data were analysed using FlowJo software (TreeStar Inc). Exon
7–9 of GNG12-AS1 was used to quantify its overexpression (primers are listed in
Supplementary Table 2).
Microarray analysis. Gene expression analysis was carried out on Illumina
Human HT12 version 4 arrays. All data analyses were carried out on R using
Bioconductor packages67. Raw intensity data from the array scanner were
processed using the BASH68 and HULK algorithms as implemented in the bead
array package69. Log2 transformation and quantile normalization of the data
were performed across all sample groups. Differential expression analysis was
carried out using the Limma package70. Differentially expressed genes were
selected using a P-value cutoff of o0.05 after application of FDR correction for
multiple testing applied globally to correct for multiple contrasts. RNA was
extracted from cells (HB2, SUM159) treated with control and GNG12-AS1
siRNAs (exons 1 and 7). The analysis was performed with six biological replicates
for each cell line. cDNA synthesis, labelling and array procedure were conducted
at the Genomic Facility at the CRUK CI. Pathway analysis was performed using
Metacore.
MeDIP (methylated DNA immunoprecipitation) qRT–PCR. Genomic DNA was
extracted from cells with control and GNG12-AS1 siRNA treated with 100mgml 1
RNaseA (Invitrogen) in 100 ml of Tris-EDTA for 10min at room temperature and
sonicated for 5min (Diagenode Picoruptor, 30 s ON-30sec OFF) to obtain an
average fragments size of 300 bp. DNA was puriﬁed using 1.8 volumes AMPURE
XP beads (Beckman Coulter) according to the manufacturer’s instructions and
resuspended in 185 ml of water. The samples were boiled for 10min and snap
frozen on ice for 10min. Five microlitres were taken as input followed by addition
of 20 ml cold 10 meDIP buffer. Meanwhile, 20 ml of Protein G Dynal beads
(Invitrogen) were blocked with PBS/0.01% BSA for 30min at room temperature
and washed three times with 1 meDIP buffer. One microlitre of anti-5mC
antibody (Diagenode) was conjugated to the washed beads in 200 ml of 1 meDIP
buffer for 2 h at room temperature. Antibody-bead conjugates were washed three
times with cold 1 meDIP buffer, added to the sample DNA and incubated
overnight at 4 C in an overhead rotator. The bound material was washed three
times with 200ml of 1 meDIP buffer at room temperature. Bound and input
material were resuspended in 50 ml lysis solution (100mM Tris-HCl, pH 5.5, 5mM
EDTA, 200mM NaCl, 0.2% SDS plus 20 mg proteinase K (Invitrogen 25530-049))
and incubated at 60 C for 30min. DNA was puriﬁed using 1.8 volumes AMPURE
XP beads (Beckman Coulter) according to the manufacturer’s instructions.
Validation of Medip was done by qRT–PCR. The list of Medip primers is present
in Supplementary Table 2.
Analysis of allelic expression and DNA methylation. Analysis of DNA
methylation was by bisulﬁte conversion with the EZ DNA Methylation-Gold Kit
(Zymo Research) and subsequent pyrosequencing as described31. The list of
primers used for this experiment is present in Supplementary Table 5.
RNA immunoprecipitation. HB2 cells were transfected with control and
GNG12-AS1 siRNAs and RIP was performed from nuclear extracts using mouse
IgG (Cell Signaling) and AGO2 (Abcam) antibodies. Quality of cytoplasmic and
nuclear extracts was assessed by immunoblot as described previously65. Eight
micrograms of antibody were incubated with 70 ml of Dynabeads Protein G beads
(Life Technologies) in total volume of 280 ml for 30min at room temperature. The
antibody–bead complex was incubated with 500mg of nuclear exactas for 2–3 h at
4 C and then washed three times (5min each) with equal amount of 1 NLB
buffer (20mM Tris-HCl, pH7.5, 0.15M NaCl, 3mM MgCl2, 0.3% NP-40,
10% glycerol) supplemented with Complete EDTA free protease inhibitor cocktail
(14549800; Roche) and phosphatase inhibitors (1mM NaF, 1mM Na3VO4) and
RNAse OUT (100U; Life Technologies). The RNA was extracted by addition of
1ml TRIzol (Life Technologies) to the beads, followed by 1/5 volume of
Chloroform (Sigma). 10% of the input lysate was mixed with 1ml of TRIzol for the
total input RNA. After centrifugation at 12,000g for 15min at 4 C, the aqueous
supernatant was transferred to a new tube and RNA was precipitated with 1/10
volume of 3M sodium acetate pH 5.5 (Life Technologies), 1 volume of isopropanol
(Sigma) and 1 ml of GlycoBLue (Life Technologies) at  80 C for 20min. After
30min centrifugation at 12,000g at 4 C, the RNA pellet was washed twice with ice-
cold 70% ethanol. Finally, the pellet was dissolved in 15 ml of RNAse-free water
(Life Technologies). We used Power SYBR Green RNA-to-CT 1-Step Kit (Life
Technologies) for qRT–PCR. Primers for this assay were GNG12-AS1 (exons 7–8)
and U1 and GAPDH (negative controls for AGO2 binding). Primers are listed in
Supplementary Table 2.
Cell lysis and immunoblot. Total cell lysis and immunoblot were performed as
described previously31. Brieﬂy, the cells were lysed in lysis buffer (50mM Tris-HCl,
pH 8, 125mM NaCl, 1% NP-40, 2mM EDTA, 1mM phenylmethylsulphonyl
ﬂuoride, and protease inhibitor cocktail (Roche)) and incubated on ice for 25min.
The proteins were denatured, reduced and separated using Nupage Novex 4–12%
Bis-Tris Protein Gels (Invitrogen). Secondary antibodies were conjugated with
peroxidase, and immunobands were detected with a Supersignal West Dura HRP
Detection Kit (Thermo-Scientiﬁc). Quantiﬁcation of immunoblots was done
on ImageScanner III (GE HealthCare) using the software package ImageQuant
TL 7.0 (GE HealthCare). Uncropped scans of the immunoblots are shown in
Supplementary Fig. 12.
Antibodies. The list of antibodies is present in Supplementary Table 6.
Chromatin immunoprecipitation. ChIP assays were performed as previously
described31 with antibodies listed in the Supplementary Table 6. The input
and the immunoprecipitated materials were quantiﬁed by QubitFluorometer
(Life Technologies) with the dsDNA BR Assay Kit (Invitrogen). Thirty micrograms
of chromatin and 5 mg of antibody were used for ChIP experiment. The qPCR data
were corrected for DNA amount, and enrichment was normalized against the input
according to the formula 2-dCt(Ab)—log2(DF)]—[Ct(input)—log2(DF)]. Primer
sequences are present in Supplementary Table 2.
Cell synchronization. The HB2 cells were plated in six-well plates and 24 h later
thymidine (2mM) was added. The cells were incubated for 18 h, washed three
times with PBS and released into thymidine-free medium for 9 h. Thymidine was
then added for a further 15 h. The cells were then washed three times with PBS. At
this point, the cells in G1/S phase were collected for RNA, FACS and protein
analysis (T0) in a serum-rich medium without thymidine. Time points were
collected 3 (T3), 8 (T8), 14 (T14), 24 (T24) and 32 (T32) hours later. In the case of
serum starvation, HB2 cells were plated in six-well plates and then switched to
serum-free medium for 48 h. After starvation (T0), the cells were released into cell
cycle by addition of serum and the time points for RNA and protein analysis were
collected at 3 (T3), 6 (T6), 10 (T10), 15 (T15) and 34 (T34) hours. Cyclin E1
(G1/S transition marker) levels were used to monitor cell cycle progression by
immunoblot. In the case of siRNA treatment, the cells were ﬁrst transfected with
siRNAs and thymidine was added 24 h later for additional 18 h. The procedure was
continued as described above.
Cell cycle analysis. The HB2 cells were transfected with siRNAs and harvested
after 72 h, washed with PBS and ﬁxed with 70% ethanol (the samples were stored
for up to 1 week at 4 C). The cells were then washed once with PBS, incubated in
PBS containing RNase A (100 mgml 1, Life Tecnologies) for 30min at 37 C,
stained with propidium iodide (20 mgml 1, Life Tecnologies) and incubated
on ice in the dark for 30min. DNA content was analysed by FACS Calibur
(Beckton Dickinson) using BD CellQuest Pro Software V6. DNA cell cycle analysis
was performed on FlowJo software V9 (TreeStar Inc) to quantify cell cycle
distribution.
Wound healing assay. Wound healing assay was performed on 24-well (Essen
Imagelock) plates in triplicates after treatment of cells with control and siRNAs
against GNG12-AS1. Forty-eight hours after siRNA treatment, scratch wounds
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were induced with 10 ml sterile pipette tip, after which fresh culture medium was
added. The IncuCyte 2011A Rev2 software was used to capture and analyse the
pictures. The cell migration was followed in time for 24 h using IncuCyte FLR
(Essen Bioscience), making measurements in triplicate every 3 h.
Statistical analysis. The statistical signiﬁcance of data was determined by two-
tailed Student’s t-test in all experiments using GraphPad Prism unless indicated
otherwise. P-values40.05 were considered statistically not signiﬁcant.
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